4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
Alzheimer's Association International Conference 2026
July 12-15, 2026 | London, United Kingdom, and Online
13221
Real-World Concordance of Blood-Based Biomarkers With CSF or PET in Suspected Alzheimer's Disease
Part of Topic
Biomarkers -> Biomarkers (non-neuroimaging) -> Fluid biomarkers
Summary:
Retrospective, single-center observational study evaluated concordance between blood-based biomarkers (BBMs) and CSF or amyloid PET in patients undergoing diagnostic evaluation for suspected Alzheimer's disease in routine neurology practice. BBM results demonstrated high concordance with CSF or amyloid PET , with only two discordant cases observed, supporting the potential utility of BBMs within real-world diagnostic workflows while highlighting the need for larger studies to validate performance estimates.
Key words:
- Alzheimer's disease (AD)
- Blood-based biomarkers (BBMs)
- Blood biomarkers
- Amyloid pathology
- Amyloid PET
- Cerebrospinal fluid (CSF)
- Biomarker concordance
- Diagnostic concordance
- Plasma biomarkers
- p-tau217
- Aβ42/40
- PrecivityAD2
- APOE ε4
- Alzheimer's diagnosis
- Mild cognitive impairment (MCI)
- Cognitive impairment
- Early diagnosis
- Real-world evidence (RWE)
- Observational study
- Diagnostic performance
- Clinical implementation
- Clinical utility
- Confirmatory testing
-
Concordance analysis
Comments
Email is required but is not shown publicly.
Loading comments...